Dr. Eman Riaz Ahmed is an IP specialist in the New York office of Wilson Sonsini Goodrich & Rosati, where she is a member of the patents and innovations practice. Her background includes molecular and cell biology, cancer therapeutics, and human nutrition in the context of disease. Eman applies her experience to patent prosecution, freedom-to-operate, and due diligence matters for clients in the life sciences, pharmaceutical, biotechnology, diagnostics, and medical devices industries.
Prior to joining the firm, Eman completed her doctorate degree at Columbia University. Her dissertation research under the supervision of Professor Brent Stockwell focused on understanding how ferroptosis and diet play a role in determining response to cancer therapies.
Dr. Eman Riaz Ahmed is an IP specialist in the New York office of Wilson Sonsini Goodrich & Rosati, where she is a member of the patents and innovations practice. Her background includes molecular and cell biology, cancer therapeutics, and human nutrition in the context of disease. Eman applies her experience to patent prosecution, freedom-to-operate, and due diligence matters for clients in the life sciences, pharmaceutical, biotechnology, diagnostics, and medical devices industries.
Prior to joining the firm, Eman completed her doctorate degree at Columbia University. Her dissertation research under the supervision of Professor Brent Stockwell focused on understanding how ferroptosis and diet play a role in determining response to cancer therapies.
- Ph.D., Biological Sciences, Columbia University, 2024
- A.B., Molecular and Cellular Biology, Harvard College, 2016
- U.S. Patent and Trademark Office (Limited recognition to practice under 37 CFR § 11.9(b))
- Ph.D., Biological Sciences, Columbia University, 2024
- A.B., Molecular and Cellular Biology, Harvard College, 2016
- U.S. Patent and Trademark Office (Limited recognition to practice under 37 CFR § 11.9(b))
Select Publications
- Co-author P.D. Bhola, J.L. Guerriero, E. Sicinska, et al., "High-throughput dynamic BH3 profiling may quickly and accurately predict effective therapies in solid tumors," 13(636) Science Signaling, 2020
- Co-author with P.S. Upadhyayula, D.M. Higgins, A. Mela, M. Banu, A. Dovas, F. Zandkarimi, P. Patel, et al., "Dietary restriction of cysteine and methionine sensitizes gliomas to ferroptosis and induces alterations in energetic metabolism," 14(1) Nature Communications 1187, 2023
Select Publications
- Co-author P.D. Bhola, J.L. Guerriero, E. Sicinska, et al., "High-throughput dynamic BH3 profiling may quickly and accurately predict effective therapies in solid tumors," 13(636) Science Signaling, 2020
- Co-author with P.S. Upadhyayula, D.M. Higgins, A. Mela, M. Banu, A. Dovas, F. Zandkarimi, P. Patel, et al., "Dietary restriction of cysteine and methionine sensitizes gliomas to ferroptosis and induces alterations in energetic metabolism," 14(1) Nature Communications 1187, 2023
Biological Sciences and Biotechnology
- Cancer biology
- Cancer therapeutics
- CAR-T cells
- Cell biology
- Cell culture products
- Cellular biology
- Cellular immunology
- Immuno-oncology
- Immunology
- Metabolomics
- Molecular biology
- T cell biology
- T cell immunology
Therapeutics and Drug Discovery
- Drug conjugates based drug discovery
- Gene editing
- Gene therapy
- Immunotherapy targets
- Pharmacology
Diagnostics and Medical Devices
- Biomedical devices
- Diagnostics
- Medical devices
Miscellaneous
- Cancer
- Fluorescence microscopy
- Food science
Biological Sciences and Biotechnology
- Cancer biology
- Cancer therapeutics
- CAR-T cells
- Cell biology
- Cell culture products
- Cellular biology
- Cellular immunology
- Immuno-oncology
- Immunology
- Metabolomics
- Molecular biology
- T cell biology
- T cell immunology
Therapeutics and Drug Discovery
- Drug conjugates based drug discovery
- Gene editing
- Gene therapy
- Immunotherapy targets
- Pharmacology
Diagnostics and Medical Devices
- Biomedical devices
- Diagnostics
- Medical devices
Miscellaneous
- Cancer
- Fluorescence microscopy
- Food science
Lila—which spun out of Nobel Laureate David Baker’s lab at the University of Washington’s Institute for Protein Design—also announced the launch of its two protein therapeutic platforms to combat cancer and non-oncology diseases. Lila’s targeted radiotherapy (TRT)/oncology platform for solid tumors and long-acting injectables (LAI) platform for non-oncology conditions are utilizing Lila’s proprietary AI/ML-powered protein design engine to create the foundation for new drug discovery and breakthrough treatments for patients. Lila’s TRT platform will be utilized in its collaboration with Lilly to generate novel tumor-targeting radiopharmaceuticals. As part of the collaboration, Lila will design precision-targeted proteins for radioligand therapy and plans to undertake program discovery through development candidate selection. Lilly will focus on IND-enabling studies, global clinical development, and commercialization. Lila will retain full asset rights to its current proprietary RLT and LAI pipelines, separate from the tumor-targeted radiotherapies they collaborate with Lilly on.
The Wilson Sonsini team that advised Lila on IP matters related to the transaction includes Michael Hostetler, Rachna Ujwal, Irene Kasumba, and Eman Riaz Ahmed.
For more information, please see Lila’s news release. Additional coverage is available on GeekWire and Inside Precision Medicine.
- Privacy Policy
- Terms of Use
- Accessibility